GLP-1 treatment linked to lower risk of hospitalization and death in older adults with fatty liver disease
A study found that GLP-1-based treatment was associated with reduced risks of hospitalization and death in older adults with fatty liver disease. The results suggest potential benefits for this group.
Older adults with fatty liver disease may benefit; evidence comes from a research study.
- population
- older adults with metabolic dysfunction-associated steatotic liver disease (MASLD)
Taken from the source as published — check the details before acting on them.
Study population
The research focused on older adults with metabolic dysfunction-associated steatotic liver disease (MASLD).
Treatment effect
GLP-1-based treatment was linked to lower risks of liver disease-related complications, hospitalization, and death.
Common questions
What condition was studied?
The study focused on metabolic dysfunction-associated steatotic liver disease (MASLD) in older adults.
What was the treatment?
The treatment involved GLP-1-based therapy, which was associated with lower risks of complications.
Sources
- GLP-1 treatment linked to lower risk of hospitalization and death in older adults with fatty liver disease MedicalXpress · medicalxpress.com
Headlines and links belong to the publishers listed above. The summary above is written by The Health Brief; see how this works.
